Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm Cmn (LGND) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 2,116,330
  • Shares Outstanding, K 20,850
  • Annual Sales, $ 71,910 K
  • Annual Income, $ 257,310 K
  • 36-Month Beta 1.36
  • Price/Sales 23.01
  • Price/Book 6.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
100.64 +1.83%
on 01/18/17
109.88 -6.73%
on 01/06/17
-1.17 (-1.13%)
since 12/23/16
3-Month
87.50 +17.12%
on 11/04/16
110.83 -7.53%
on 11/14/16
+8.97 (+9.59%)
since 10/21/16
52-Week
82.06 +24.88%
on 02/11/16
139.79 -26.69%
on 08/01/16
-0.09 (-0.09%)
since 01/22/16

Most Recent Stories

More News
EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 13, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 12, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017

NEW YORK, NY / ACCESSWIRE / January 11, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated ("Ligand" or the...

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 10, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

LGND SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / January 6, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017

NEW YORK, NY / ACCESSWIRE / January 6, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Ligand Pharmaceuticals Incorporated ("Ligand" or the...

LGND LOSS ALERT: Rosen Law Firm Reminds Ligand Pharmaceuticals Incorporated Investors of Important January 17 Deadline in Class Action Filed by Firm - LGND

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through November 14, 2016, both dates inclusive...

SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 5, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:...

LGND INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ligand Pharmaceuticals Inc. and a Lead Plaintiff Deadline of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc....

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Support & Resistance

2nd Resistance Point 106.51
1st Resistance Point 104.85
Last Price 102.31
1st Support Level 101.78
2nd Support Level 100.37

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.